Table 2 Comparison between the remission or low disease activity group (L group) and moderate or high disease activity group (H group) by DAS28

Total patients

1133

705

Age (years)

64.2±13.0

70.0±12.2

<0.0001*

Sex—male/female

251 (22.2)/882 (77.8)

114 (16.2)/591 (83.8)

0.0017*

Disease duration (months)

145±120

162±141

0.0055*

Steinbrocker stage I/II/III/IV

33.8/21.9/21.9/22.4

18.8/22.7/27.5/31.0

<0.0001*

Steinbrocker class I/II/III/IV

59.5/33.5/5.7/1.3

25.8/49.5/20.3/4.4

<0.0001*

ACPA (U/ml)

114±173

181±436

0.0034*

DAS

2.2±0.7

4.1±0.8

<0.0001*

SDAI

3.9±3.2

12.7±7.5

<0.0001*

HAQ

0.5±1.1

1.4±3.6

<0.0001*

DMARDs usage

1133 (61.6)

705 (38.4)

0.0017*

 MTX usage

711 (62.7)

406 (57.6)

0.0387*

 MTX dose (mg/week)

7.3±2.3

7.2±2.4

0.5686

PSL usage

370 (32.7)

341 (48.4)

<0.0001*

PSL dose (mg/day)

3.5±2.1

4.1±2.1

<0.0001*

Biologics/JAK usage

346 (30.5)

155 (22.0)

<0.0001*

 Hypertension

312 (27.5)

307 (43.5)

<0.0001*

 Diabetes mellitus

73 (6.4)

76 (10.8)

0.0011*

 Respiratory disease

104 (9.2)

120 (17.0)

<0.0001*

 Cerebrovascular disease

32 (2.8)

54 (7.7)

<0.0001*

 Cardiovascular disease

71 (6.2)

72 (10.2)

0.0030*

 Renal disease

310 (27.4)

256 (36.3)

0.0562

 Malignant tumor

60 (5.3)

45 (6.4)

0.5695